TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has entered into an agreement with The University of Texas Southwestern Medical Center (UT Southwestern Medical Center) that will provide researchers at the Dallas-based medical center with access to Regeneron’s VelocImmune technology to discover fully human monoclonal antibodies.
